JO3654B1 - مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa) - Google Patents

مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)

Info

Publication number
JO3654B1
JO3654B1 JOP/2016/0085A JOP20160085A JO3654B1 JO 3654 B1 JO3654 B1 JO 3654B1 JO P20160085 A JOP20160085 A JO P20160085A JO 3654 B1 JO3654 B1 JO 3654B1
Authority
JO
Jordan
Prior art keywords
benzimidazoles
aza
receptor modulators
ampa receptor
compounds
Prior art date
Application number
JOP/2016/0085A
Other languages
English (en)
Inventor
M Savall Bradley
Wu Dongpei
M Swanson Devin
Patrick Lebold Terry
K Ameriks Michael
G B Berry Cynthia
Loic Jourdan Fabrice
Angel Pena Pi??N Miguel
Chen Gang
Ravula Suchitra
Wei LIN David
Zhang Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3654B1 publication Critical patent/JO3654B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتوفر بهذا الاختراع مركبات بالصيغة (I) وأملاحها المقبولة صيدلانيًا أو أكاسيدها النيتروجينية أو تذاوباتها، (I) يتوفر بهذا الاختراع أيضًا مركبات صيدلانية تتضمن مركبات بالصيغة (I) وطرق استخدام مركبات بالصيغة (I).
JOP/2016/0085A 2015-04-29 2016-04-28 مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa) JO3654B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
JO3654B1 true JO3654B1 (ar) 2020-08-27

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0085A JO3654B1 (ar) 2015-04-29 2016-04-28 مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)

Country Status (39)

Country Link
US (5) US11312712B2 (ar)
EP (3) EP4144736B1 (ar)
JP (2) JP6800886B2 (ar)
KR (2) KR102782808B1 (ar)
CN (1) CN107835814B (ar)
AR (1) AR104447A1 (ar)
AU (2) AU2016255434C1 (ar)
BR (2) BR122023023802A2 (ar)
CA (1) CA2983826A1 (ar)
CO (1) CO2017011017A2 (ar)
CR (1) CR20170484A (ar)
CY (1) CY1124059T1 (ar)
DK (1) DK3288940T5 (ar)
EA (1) EA033281B1 (ar)
EC (1) ECSP17074645A (ar)
ES (1) ES2865330T3 (ar)
GT (1) GT201700231A (ar)
HR (1) HRP20210403T1 (ar)
HU (1) HUE053943T2 (ar)
IL (1) IL254848B (ar)
JO (1) JO3654B1 (ar)
LT (1) LT3288940T (ar)
MA (1) MA41988B1 (ar)
MD (1) MD3288940T2 (ar)
MX (1) MX376113B (ar)
MY (1) MY194104A (ar)
NI (1) NI201700129A (ar)
PH (1) PH12017501816B1 (ar)
PL (1) PL3288940T3 (ar)
PT (1) PT3288940T (ar)
RS (1) RS61688B1 (ar)
SG (1) SG11201708190UA (ar)
SI (1) SI3288940T1 (ar)
SM (1) SMT202100222T1 (ar)
TW (1) TWI706952B (ar)
UA (1) UA120304C2 (ar)
UY (1) UY36654A (ar)
WO (1) WO2016176460A1 (ar)
ZA (1) ZA201708065B (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865330T3 (es) 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
MX373652B (es) * 2015-04-29 2020-04-02 Janssen Pharmaceutica Nv Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CA3287539A1 (en) 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
ES2971497T3 (es) * 2017-10-06 2024-06-05 Takeda Pharmaceuticals Co Compuestos heterocíclicos
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
AU2019373416A1 (en) * 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
JP2023554393A (ja) * 2020-12-16 2023-12-27 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法
CN117402148A (zh) * 2023-07-26 2024-01-16 青岛大学 一种氮-氮苯并咪唑轴手性化合物及其制备方法和应用
WO2025155830A1 (en) 2024-01-17 2025-07-24 Rapport Therapeutics, Inc. Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy
KR20250113344A (ko) * 2024-01-17 2025-07-25 주식회사 엘지화학 CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물
WO2025217330A1 (en) * 2024-04-10 2025-10-16 Terremoto Biosciences, Inc. Cysteine covalent modifiers of akt1 and uses thereof
WO2025231416A1 (en) * 2024-05-03 2025-11-06 Rapport Therapeutics, Inc. Methods of use of ampa receptor modulators

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (ar) * 1992-11-02 1995-07-11 Pfizer
JP2829788B2 (ja) 1994-02-10 1998-12-02 ファイザー インク． ベンゾジアゼピン受容体部位アゴニスト及びアンタゴニストとしての５−ヘテロアリールインドール誘導体
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
US6613777B1 (en) 1998-03-06 2003-09-02 Chen Chen CRF antagonistic pyrazolo[4,3-b]pyridines
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
MXPA01006742A (es) 1998-12-31 2004-04-21 Sugen Inc Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer.
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
EP1309577A2 (en) 2000-08-11 2003-05-14 Eli Lilly And Company Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CN101052640B (zh) * 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
DE602007013450D1 (de) 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
US8450343B2 (en) 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
WO2010005528A2 (en) 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
EP2533639A4 (en) 2010-02-11 2013-08-21 Univ Vanderbilt PYRAZOLOPYRIDIN, PYRAZOLOPYRZIN, PYRAZOLOPYRIMIDIN, PYRAZOLOTHIOPHEN AND PYRAZOLOTHIAZOL COMPOUNDS AS ALLOSTERIC MGLUR4 POTENTRANS AND COMPOUNDS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
WO2011163355A1 (en) 2010-06-24 2011-12-29 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
US9150591B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP2603079B1 (en) 2010-08-12 2018-09-19 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
WO2013130501A1 (en) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
BR112015019276A2 (pt) * 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
ES2865330T3 (es) 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
JP6953527B2 (ja) 2016-10-26 2021-10-27 ヤンセン ファーマシューティカ エヌ．ベー． 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
AU2017350688B2 (en) 2016-10-26 2021-04-01 Rapport Therapeutics, Inc. Fused azaheterocyclic compounds and their use as AMPA receptor modulators
WO2018080918A1 (en) 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv 3-aryl-2h-pyrazolo[4,3-b]pyridine compounds and their use as ampa receptor modulators
EP3774739B1 (en) 2018-04-09 2022-05-11 RaQualia Pharma Inc. Fused cyclic urea derivatives as crhr2 antagonist
US12479845B2 (en) 2019-02-01 2025-11-25 Hanmi Pharm. Co., Ltd. Imidazopyridine derivative compounds and use of same

Also Published As

Publication number Publication date
JP6800886B2 (ja) 2020-12-16
SMT202100222T1 (it) 2021-05-07
JP2021042230A (ja) 2021-03-18
UY36654A (es) 2016-10-31
CN107835814B (zh) 2021-07-23
CR20170484A (es) 2018-02-26
SG11201708190UA (en) 2017-11-29
PH12017501816B1 (en) 2023-07-19
AR104447A1 (es) 2017-07-19
PT3288940T (pt) 2021-04-30
AU2020210231B2 (en) 2021-07-22
EP3288940B9 (en) 2021-07-21
AU2016255434A1 (en) 2017-10-26
US11312712B2 (en) 2022-04-26
LT3288940T (lt) 2021-05-10
DK3288940T3 (da) 2021-05-25
HK1252249A1 (en) 2019-05-24
CA2983826A1 (en) 2016-11-03
BR112017023147A2 (pt) 2018-07-10
AU2016255434C1 (en) 2021-09-23
NI201700129A (es) 2019-05-10
TW201708217A (zh) 2017-03-01
US12139485B2 (en) 2024-11-12
TWI706952B (zh) 2020-10-11
US20230114165A1 (en) 2023-04-13
EP3288940B1 (en) 2021-02-24
ZA201708065B (en) 2019-09-25
EP3901153A1 (en) 2021-10-27
IL254848B (en) 2021-01-31
UA120304C2 (uk) 2019-11-11
CY1124059T1 (el) 2022-05-27
EP4144736A1 (en) 2023-03-08
NZ736057A (en) 2023-08-25
US20210284641A1 (en) 2021-09-16
KR20170140382A (ko) 2017-12-20
JP7026194B2 (ja) 2022-02-25
US20230110576A1 (en) 2023-04-13
MX376113B (es) 2025-03-07
EA201792374A1 (ru) 2018-05-31
CO2017011017A2 (es) 2018-03-20
CN107835814A (zh) 2018-03-23
US12145934B2 (en) 2024-11-19
AU2016255434B2 (en) 2020-05-14
BR122023023802A2 (pt) 2023-12-26
US20180118740A1 (en) 2018-05-03
DK3288940T5 (da) 2021-09-20
MD3288940T2 (ro) 2021-08-31
EA033281B1 (ru) 2019-09-30
IL254848A0 (en) 2017-12-31
HUE053943T2 (hu) 2021-08-30
NZ774642A (en) 2024-09-27
MY194104A (en) 2022-11-11
MA41988A (fr) 2018-07-03
BR112017023147B1 (pt) 2024-04-30
KR102782808B1 (ko) 2025-03-14
PL3288940T3 (pl) 2021-07-12
SI3288940T1 (sl) 2021-07-30
US12304908B2 (en) 2025-05-20
HRP20210403T1 (hr) 2021-10-29
GT201700231A (es) 2018-12-20
MX2017013886A (es) 2018-03-12
ES2865330T3 (es) 2021-10-15
EP3288940A1 (en) 2018-03-07
PH12017501816A1 (en) 2018-04-23
RS61688B1 (sr) 2021-05-31
EP4144736B1 (en) 2026-05-06
JP2018518462A (ja) 2018-07-12
US20250230157A1 (en) 2025-07-17
MA41988B1 (fr) 2021-03-31
ECSP17074645A (es) 2018-02-28
AU2020210231A1 (en) 2020-08-20
KR20240017991A (ko) 2024-02-08
WO2016176460A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
JO3654B1 (ar) مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa)
JOP20190174B1 (ar) مثبطات jak1 انتقائية
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
EA201591420A1 (ru) Гетероарильные соединения и их применение
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
MX375184B (es) Inhibidores de prmt5 y sus usos.
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
TW201613864A (en) Novel compounds
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
MX384798B (es) Piridinona dicarboxamida para uso como inhibidores de bromodominio.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
JOP20190049A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
JOP20170115B1 (ar) مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
EA201991141A1 (ru) Усилители bmp
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.